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Objective To investigate the effect of vitamin D supplementation dose on allergic sensitization and allergic dis-
eases in infants, and to evaluate whether vitamin D status in pregnancy and at birth are associated with infant allergy
outcomes.
Study design Altogether, 975 infants participated in a randomized, controlled trial of daily vitamin D supplemen-
tation of 10 mg (400 IU) or 30 mg (1200 IU) from the age of 2 weeks. At 12 months of age, food and aeroallergen IgE
antibodies were measured, and the occurrence of allergic diseases and wheezing were evaluated.
ResultsWe found no differences between the vitamin D supplementation groups in food (OR, 0.98; 95%CI, 0.66-
1.46) or aeroallergen sensitization at 12 months (OR, 0.76; 95%CI,0.34-1.71). Allergic diseases or wheezing did not
differ between groups, except for milk allergy which occurred more often in infants administered 30 mg vitamin D
compared with the 10 mg dose (OR, 2.23; 95% CI, 1.00-4.96). Infants with high cord blood 25-hydroxyvitamin D
(³100 nmol/L) had a higher risk of food allergen sensitization compared with those with lower 25(OH)D concentra-
tion (75-99.9 nmol/L; OR, 2.00; 95% CI, 1.19-3.39).
Conclusions High-dose vitamin D supplementation did not prevent allergic sensitization, allergic diseases, or
wheezing during the first year of life. In contrast, we observed an increased risk of milk allergy in infants randomized
to higher vitamin D supplementation, and an increased risk of allergic sensitization in infants with high cord blood
vitamin D status, indicating a possible adverse effect of high concentrations of vitamin D. (J Pediatr 2019;-:1-7).O
bservational studies demonstrate a link between vitamin D status at birth and the development of allergic diseases. The
results are, however, inconsistent. In a Taiwanese birth cohort, maternal vitamin D status was inversely related to
allergic sensitization and atopic diseases in the offspring, whereas another study reported positive association of
maternal and cord blood 25-hydroxyvitamin (25(OH)D) levels with children’s risk for food allergy and allergic sensitization
during the first 2 years of life.1,2 A longitudinal follow-up study of children from birth to age 5 years found persistent vitamin D
deficiency in childhood to be associated with eosinophilia and allergic sensitization.3
Similarly, some studies have reported vitamin D deficiency during pregnancy or in early childhood to be a risk factor for
wheezing and later development of asthma,4,5 whereas others have found no association.6 Three randomized, controlled trials
on vitamin D supplementation during pregnancy in prevention of allergic diseases and wheezing have been conducted.7-10 One
study examined the effect of maternal vitamin D supplementation during lactation on infantile allergic disorders, but no large-
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age.12 Mothers were of northern European ethnicity without
regular medication and with a singleton pregnancy. Infants
included in the study were born at term (370/7 to 420/7 weeks
of gestation) with a birth weight appropriate for gestational
age (birth weight SDS between 2.0 and +2.0). Those
requiring intravenous glucose, antibiotics, nasal continuous
positive airway pressure for >1 day, phototherapy for
>3 days, or nasogastric tube feeding for >1 day, and with sei-
zures were excluded. Study recruitment occurred between
January 2013 and June 2014. We obtained written informed
consent from the parents. The study was conducted in accor-
dance with the Declaration of Helsinki, and the Research
Ethics Committee of the Hospital District of Helsinki and
Uusimaa provided ethical approval (107/13/03/03/2012).
The project protocol is registered on ClinicalTrials.gov
(NCT01723852) and has been reported previously.
12,13
Randomization to the 2 vitamin D supplementation
groups was performed in blocks of 50 by a pharmacist at Hel-
sinki University Hospital Pharmacy. Study preparations,
identical in appearance, contained vitamin D3 dissolved in
medium-chain triglyceride oil (Orion Pharmaceuticals, Es-
poo, Finland) and were administered orally with 5 drops
for both groups. The use of other vitamin D supplements
was not allowed during the study. The study was double
blinded, with participants and investigators masked to group
assignment. Compliance with the vitamin D supplementa-
tion was assessed from study diaries in which the parents pro-
spectively recorded dosing of the supplement.
Data Collection
Family demographics were obtained from hospital records
and structured questionnaires during follow-up. Pregnancy
serum samples were collected at 11 weeks of gestation on
average during routine follow-up visits at prenatal clinics
and stored in the Finnish Maternity Cohort serum bank
maintained by the National Institute for Health and Welfare.
We measured the 25(OH)D concentration from pregnancy
serum samples, cord blood, and at 12 months with a fully
automated immunoassay (IDS-iSYS, Immunodiagnostic
System Ltd., Bolton, UK).12 At 12 months, we measured spe-
cific IgE antibodies toward food allergens (cow’s milk, egg
white, wheat, cod, peanut, soy) and toward aeroallergens
(birch, mugwort, timothy, horse, cat, dog, Dermatophagoides
pteronyssinus, and Cladosporium herbarum) with Immuno-
CAP (Phadia, Uppsala, Sweden) at the Laboratory of Hel-
sinki University Hospital. Allergic sensitization to food or
aeroallergens was defined as a specific IgE concentration of
³0.35 kU/L.
At 12 months, parents completed structured allergy ques-
tionnaires based on a modified International Study of
Asthma and Allergies in Childhood questionnaire that
included questions on occurrence of physician-diagnosed
food allergy ever (cow’s milk, wheat, or any food), atopic
eczema, or asthma, and allergy symptoms in the child.14 Al-
lergy symptoms including wheezing or breathing difficulty,
persistent cough, and itchy rash were queried. Wheezing or2breathing difficulty was defined as a positive answer to the
question, “Has your child ever had wheezing or difficulty
in breathing in the preceding 12 months?” Persistent cough
was defined as a positive answer to the question, “Has your
child had persistent coughing for at least 6 weeks in the pre-
ceding 12 months?” Itchy rash was defined as a positive
answer to the question, “Has your child had dry, red or itchy
skin requiring regular care in the preceding 12 months?”
The number of hospitalizations owing to bronchiolitis or
wheezing during the first 12 months was calculated from
study diaries in which parents recorded all their child’s infec-
tions including data on infection type, symptoms, medica-
tion, and possible hospitalization during the vitamin D
intervention trial.12
At 12 months, the dietary intake of vitamin D was deter-
mined from a 3-day food record administered by the parents
or daycare personnel. Nutrient intakes were processed with
AivoDiet software (Aivo Oy Finland, Turku, Finland), which
used Fineli, the National Food Composition Database main-
tained by the National Institute for Health and Welfare,
Finland. The calculated total vitamin D intake did not
include intake from breast milk.12
Statistical Analyses
Normality of the continuous variables was determined by vi-
sual inspection and with the Kolmogorov-Smirnov test of
normality. For group comparisons, independent samples t-
test or Mann-WhitneyU test were used in case of continuous
variables and the Pearson c2 or Fisher exact test in case of cat-
egorical variables. To evaluate the effect of vitamin D supple-
mentation group on food or aeroallergen sensitization and
clinical allergy outcomes, logistic regression was applied,
with adjustment for potential confounders based on the asso-
ciations observed in the present study. Similarly, logistic
regression was used to evaluate the effect of pregnancy,
cord blood, and the 25(OH)D concentration at 12 months
on food allergen sensitization. All analyses were performed
by intention-to-treat principle using SPSS software (IBM




A total of 975 infants fulfilled the trial inclusion criteria; 489
were randomized to 10 mg and 486 to 30 mg daily vitamin D
supplementation. Study enrollment, allocation, and follow-
up is presented (Figure; available at www.jpeds.com).
At 12 months, a total of 865 infants (91.5%) attended the
follow-up visit. Parental history of allergic diseases or other
baseline characteristics did not differ between intervention
groups (Table I). Breastfeeding was continued for
>6 months for 78.9% of the infants, with a mean duration
of 10.7 months. Pregnancy or baseline cord blood 25(OH)
D concentrations did not differ between the intervention
groups (Table I). In pregnancy and at birth, 96.5% of the
mothers and 95.7% of the infants, respectively, wereRosendahl et al
Table I. Characteristics of the study participants






Child 489/975 (50) 486/975 (50)
Girls 242/489 (50) 243/486 (50)
Boys 247/489 (50) 243/486 (50)
Birth weight, g* 3514  379 3565  410
Birth length, cm 50.3  2 50.4  2
Season of birth
Winter 100/489 (20) 89/486 (18)
Spring 197/489 (40) 203/486 (42)
Summer 108/489 (22) 109/486 (22)
Autumn 84/489 (17) 85/486 (17)
Siblings 153/444 (34) 178/448 (40)
Breastfeeding >6 months 330/428 (77) 344/426 (81)
Daycare attendance at 12 months 15/435 (3) 23/431 (5)
Pets 131/380 (35) 129/377 (34)
Baseline 25(OH)D
concentration, nmol/L†
Pregnancy 82.0  22.1 81.6  18.0
Cord blood 81.7 (28) 81.3 (24)
Mother
History of allergic disease
Asthma 28/403 (7) 30/411 (7)
Allergic rhinitis 128/403 (32) 123/411 (30)
Atopic eczema 74/403 (18) 61/411 (15)
Food allergy 70/403 (17) 59/411 (14)
Smoking 17/427 (4) 15/442 (3)
Educational level‡
Low 119/437 (27) 107/446 (24)
High 318/437 (73) 339/446 (76)
Use of vitamin D supplements
in pregnancy
407/430 (95) 406/433 (94)
Father
History of allergic disease
Asthma 27/403 (7) 38/411 (9)
Allergic rhinitis 136/403 (34) 158/411 (39)
Atopic eczema 47/403 (12) 44/411 (11)
Food allergy 56/403 (14) 62/411 (15)
Smoking 60/419 (14) 64/425 (15)
Educational level‡
Low 164/434 (38) 164/436 (38)
High 270/434 (62) 272/436 (62)
Values are n/N (%) or mean  SD.
*Statistically significant difference between groups (P = .042).
†n = 809 for pregnancy 25(OH)D; n = 955 for cord blood 25(OH)D.
‡Low is defined as less than a bachelor’s degree and high as at least a bachelor’s degree.
- 2019 ORIGINAL ARTICLESvitamin D sufficient, defined as 25(OH)D ³50 nmol/L. At
12 months, the mean 25(OH)D concentration was
significantly higher in the 30 mg vitamin D group
compared with the 10 mg group (115.0 nmol/L vs
82.7 nmol/L; P < .001). At 12 months, the mean daily
vitamin D intake from food was 6.2 (SD, 3.7) mg with no
differences between the groups (P = .322).
Effect of Vitamin D Supplementation on IgE
Sensitization
At 12 months of age, we obtained serum samples for mea-
surement of specific IgE antibodies from 723 of the 975
children (74.2%; ie, from 83.6% of those attending the
12-month follow-up visit). IgE sensitization to food aller-
gens was observed in 114 of 723 children (15.8%) and to
aeroallergens in 25 of 719 children (3.5%). Food IgE sensi-High-Dose Vitamin D Supplementation Does Not Prevent Allergictization was most common to egg white (10.4%) and cow’s
milk (5.8%; Table II) and occurred more often in children
born to parents with a history of allergic disease (OR, 1.16;
95% CI, 1.02-1.33) and in those attending daycare at
12 months (OR, 2.45; 95% CI, 1.13-5.29). Season of birth,
duration of breastfeeding, existence of older siblings, or
parental smoking did not affect the risk of allergic
sensitization at 12 months. We found no difference in
specific IgE sensitization between the intervention groups
(Table II). The results did not change after adjustment
for potential confounding factors (ie, parental history of
allergy or daycare attendance). We also repeated the
analyses using a higher cut-off for food IgE sensitization
(ie, food IgE of >0.5 and 5.0 kU/L), but the findings
remained unaltered showing no differences in IgE
sensitization between the groups. The distribution of
cow’s milk IgE did not differ between groups: the mean
cow’s milk IgE was 0.94 (SD 2.3) kU/L in the 10 mg
vitamin D group and 1.35 (SD 4.2) kU/L in the 30 mg
group (P = .866). No statistically significant differences
were seen in cow’s milk IgE sensitization stratified by
birth season (P = .872).
Effect of Vitamin D Supplementation on Allergic
Diseases and Allergy Symptoms
Data on physician-diagnosed allergic diseases and allergy
symptoms reported by parents were obtained from 770 of
975 children (79%) at 12months.We found no difference be-
tween the intervention groups in physician-diagnosed wheat
allergy, any food allergy, atopic eczema, or asthma
(Table III). Physician-diagnosed cow’s milk allergy was
reported more often in the group receiving 30 mg vitamin
D supplementation compared with the 10 mg vitamin D
group (20/387 [5.2%] vs 9/377 [2.4%]; P = .044;
Table III). The findings were unaltered after adjustment
for potential confounding factors, that is, a parental history
of allergic disease and the duration of breastfeeding. Of
infants with reported cow’s milk allergy (n = 29), IgE
sensitization to cow’s milk was observed in only 4 of 25
children (16%; 4 missing blood samples).
Wheezing or breathing difficulty during the first year of life
was reported in 76 of 763 of the cohort (10.1%) with no dif-
ference between the intervention groups (Table III).
Likewise, the number of children hospitalized for
bronchiolitis or wheezing was similar in both groups
(Table III). At 12 months, physician-diagnosed asthma was
rare, with only 1 child reported to have an asthma diagnosis.
Allergic Sensitization according to Vitamin D Status
We observed no correlation between pregnancy or cord
blood 25(OH)D and specific food or aeroallergens IgE con-
centrations at 12 months (P > .1 for all). However, when
dividing cord blood 25(OH)D concentration in subgroups
<75 nmol/L (n = 295), 75.0-99.9 nmol/L (n = 286), and
³100 nmol/L (n = 126), the risk for IgE sensitization to
food allergens was higher in infants with cord blood
25(OH)D concentration was >100 nmol/L compared withSensitization of Infants 3
Table II. Allergic sensitization to food or aeroallergens at 12 months in infants randomized to 10 mg or 30 mg vitamin
D supplementation
Allergic sensitizations at 12 months All Vitamin D 10 mg Vitamin D 30 mg P value* OR (95% CI)†
Food IgE sensitization 114/723 (15.8) 57/358 (15.9) 57/365 (15.6) .910 0.98 (0.66-1.46)
Cow’s milk 42/720 (5.8) 21/358 (5.9) 21/362 (5.8) .974
Wheat 17/720 (2.4) 10/358 (2.8) 7/362 (1.9) .448
Egg white 75/720 (10.4) 40/358 (11.2) 35/362 (9.7) .509
Cod 3/720 (0.4) 2/358 (0.6) 1/362 (0.3) .622
Soybean 8/720 (1.1) 6/358 (1.7) 2/362 (0.6) .175
Peanut 23/720 (3.2) 16/358 (4.5) 7/362 (1.5) .053
Aeroallergen IgE sensitization 25/719 (3.5) 14/356 (3.9) 11/363 (3.0) .509 0.76 (0.34-1.71)
Birch 10/718 (1.4) 6/356 (1.7) 4/362 (1.1) .543
Mugwort 0/718 0 0 ‡
Timothy 3/718 (0.4) 3/356 (0.8) 0/362 (0) .121
Dog 13/718 (1.8) 7/356 (2.0) 6/362 (1.7) .765
Cat 10/718 (1.4) 5/356 (1.4) 5/362 (1.4) 0.979
Horse 2/716 (0.3) 2/355 (0.6) 0/361 (0) .245
Dermatophagoides pteronyssinus 1/718 (0.1) 1/356 (0.3) 0/362 (0) .496
Cladosporium herbarum 1/718 (0.1) 1/356 (0.3) 0/362 (0) .496
Allergic sensitization defined as serum food or aeroallergen IgE of ³0.35 kU/L.Total food and aeroallergen IgE sensitization is presented in bold.
Values are n/N (%).
*P values are from a Pearson c2 or Fisher exact test when the cell count is £5.
†OR from logistic regression with 95% CI.
‡Not applicable owing to the small number of subjects.
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(OR, 2.00; 95% CI, 1.19-3.39; Table IV). The finding
persisted after adjustment for potential confounding
factors, including adjustment for the intervention group
(Table IV). No similar effect was seen when analyzed by
pregnancy 25(OH)D concentration (Table IV). When
analyzed according to 25(OH)D concentration measured at
12 months divided in the same subgroups (<75.0, 75.0-
99.9, ³100 nmol/L), we found no difference in allergic
sensitization to food allergens in the unadjusted model
(Table IV). However, in the adjusted analysis, the risk for
food IgE sensitization was higher in infants with a 25(OH)
D concentration at 12 month of >100 nmol/L compared
with those with a concentration between 75.0 and
99.9 nmol/L. Proportions of aeroallergen-positive infants
did not differ according to maternal, cord blood, or
25(OH)D concentration at 12 months (data not shown).Table III. Parental report of physician-diagnosed allergic di
randomized to 10 or 30 mg vitamin D supplementation
Allergic disease or symptoms All Vit
Physician-diagnosed allergic disease
Cow’s milk allergy 29/764 (3.8)
Wheat allergy 11/762 (1.4)
Any food allergy 47/770 (6.1) 2
Atopic eczema 128/769 (16.6) 7
Asthma 1/765 (0.1)
Allergy symptoms
Wheezing or breathing difficulty 76/763 (10.0) 3
Hospitalization owing to bronchiolitis or wheezing 25/901 (2.8) 1
Persistent cough 46/756 (6.1) 2
Itchy rash 126/765 (16.5) 7
Values are n/N (%) unless otherwise indicated.
*P values from Pearson c2 or Fisher exact test when the cell count is £5.
†OR from logistic regression with 95% CI.
‡Not applicable owing to small the number of subjects.
4Discussion
In this randomized, controlled trial comparing daily vitamin
D supplementation of 10 mg and 30 mg in infancy, we
observed no differences in allergic sensitization between the
groups at 12 months of age. Physician-diagnosed allergic dis-
eases and occurrence of wheezing were similar in both inter-
vention groups. Exception was for cow’s milk allergy, which
was reported more often in infants administered 30 mg
vitamin D daily compared with the 10 mg dose. In addition,
we observed that infants with high cord blood 25(OH)D
levels before the intervention had an increased risk for
allergic sensitization compared with those with a lower
vitamin D status. The main observation of our study is that
increasing vitamin D status by higher vitamin D supplemen-
tation in infancy does not protect from allergic sensitization,
allergic diseases, or wheezing during the first year of life.sease and allergy symptoms at 12 months in infants
amin D 10 mg Vitamin D 30 mg P value* OR (95% CI)†
9/377 (2.4) 20/387 (5.2) .044 2.23 (1.00-4.96)
5/377 (1.3) 6/385 (1.6) .788 1.18 (0.36-3.89)
0/382 (5.2) 27/388 (7.0) .318 1.35 (0.75-2.46)
2/381 (18.9) 56/388 (14.4) .097 0.72 (0.49-1.01)
1/378 (0.3) 0/387 (0) .494 ‡
9/380 (10.3) 37/383 (9.7) .781 0.94 (0.58-1.50)
4/451 (3.1) 11/450 (2.4) .547 0.78 (0.35-1.74)
0/377 (5.3) 26/379 (6.9) .371 1.32 (0.72-2.40)
2/380 (18.9) 54/385 (16.5) .067 0.70 (0.48-1.03)
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Table IV. Allergic sensitization to food allergens at 12 months by 25(OH)D concentration in pregnancy, cord blood
and at 12 months
25(OH)Ds (nmol/L)
Food IgE sensitization (‡0.35 kU/L)
n/N (%) Unadjusted OR (95% CI)* P value Adjusted OR (95% CI)† P value
Pregnancy
<75.0 38/224 (17.9) 1.28 (0.79-2.08) .313 1.40 (0.83-2.35) .202
75.0-99.9 40/291 (13.7) Reference Reference
³100 20/99 (20.2) 1.59 (0.88-2.88) .126 1.47 (0.76-2.89) .244
Cord blood
<75.0 43/295 (14.6) 1.05 (0.66-1.67) .839 1.11 (0.67-1.85) .689
75.0-99.9 40/286 (14.0) Reference Reference
³100 31/126 (24.6) 2.00 (1.19-3.39) .009 2.18 (1.25-3.80) .006
12 months
<75.0 26/149 (17.4) 1.32 (0.76-2.30) .331 1.82 (0.96-3.47) .069
75.0-99.9 34/246 (13.8) Reference Reference
³100 54/325 (16.6) 1.24 (0.78-1.98) .360 2.10 (1.18-3.71) .011
*OR from logistic regression with 95% CI.
†Adjusted for vitamin D supplementation group, sex, parental allergy history, and attendance in daycare at 12 months of age.
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supplementation on allergic diseases in a randomized,
controlled setting. Prenatal vitamin D supplementation
studies show mixed results. Vitamin D supplementation,
administered daily or in a single dose during the third
trimester of pregnancy, did not decrease the risk of allergic
diseases in the first 3 years of life.7 Two randomized trials
examined high-dose (70 mg/d and 110 mg/d) vitamin D sup-
plementation regimens compared with a standard dose
(10 mg/d) during pregnancy on the risk of recurrent
wheezing, asthma, or eczema in the offspring at 3 years of
age.8,9 Both studies failed to report a statistically significant
decrease in the risk of asthma/wheeze with higher prenatal
vitamin D supplementation compared with the standard
dose. Subsequently, the 2 research groups performed a com-
bined analysis of these trials, which showed that risk of
asthma/recurrent wheeze was in fact decreased by 26% in
the offspring.15
We found no effect of postnatal vitamin D supplementa-
tion on the risk of wheezing at 12 months. It has been sug-
gested that vitamin D has a role in fetal lung development,
and vitamin D deficiency alters normal lung function and
structure.16,17 Our mothers and infants were, however,
mostly vitamin D sufficient during pregnancy and at birth,
and during the intervention the 25(OH)D concentration
increased to relatively high levels in the 30 mg vitamin D
group. Our results indicate that, in already vitamin D-suffi-
cient infants, there is no advantage of higher vitamin D sup-
plementation against wheezing in the early postnatal period.
This finding is supported by our initial finding of vitamin D
supplementation not decreasing the incidence of infections
during the first 2 years of life, because early childhood
wheezing is often related to respiratory infections.12
Unexpectedly, the occurrence of cow’s milk allergy was
more frequent in infants supplemented with 30 mg of vitamin
D compared with the 10 mg dose. The association of vitamin
D supplementation in infancy and an increased risk of
allergic conditions have also been reported by others. In aHigh-Dose Vitamin D Supplementation Does Not Prevent AllergicFinnish population-based study, high-dose vitamin D sup-
plementation in infancy was associated with an increased
risk of atopy, allergic rhinitis, and asthma in adulthood.18
Similarly, in a Japanese study, short-term vitamin D supple-
mentation of lactating mothers of breast-fed infants with
facial eczema did not decrease the severity of infantile
eczema, but instead increased the risk of later food allergy.11
Furthermore, Weisse et al reported that maternal and cord
blood 25(OH)D levels were positively associated with chil-
dren’s risk for food allergy and food allergen sensitization
during the first 2 years of life.2
The risk of IgE sensitization to food allergens at 12 months
of age differed according to cord blood vitamin D status. We
observed that infants with cord blood 25(OH)D concentra-
tions in the highest range (>100 nmol/L) had increased the
odds of food IgE sensitization at 12 months. Previously, con-
flicting results have been reported. Both low, and, similar to
our study, high cord blood 25(OH)D concentrations have
been associated with IgE sensitization, suggesting more a
U-shaped or nonlinear association.19-21 Because vitamin D
deficiency (<50 nmol/L) was rare in our cohort, we could
not confirm the U-shaped association.
The molecular mechanisms of the immunomodulatory ef-
fects of vitamin D are not fully understood. Vitamin D has
effects on the innate and adaptive immune response, and
for example induces antimicrobial peptide production, and
modulates T-cell, dendritic cell, and B-cell functions.22 In
relation to allergy, vitamin D may be important in the main-
tenance of type 1 T helper cell–type 2 T helper cell balance,
and by modulating regulatory T cells, which are essential in
development of immune tolerance.23 Interestingly, 2 studies
reported a correlation between high cord blood 25(OH)D
levels and low numbers of cord blood regulatory T cells,
providing a biological explanation for how high 25(OH)D
levels could increase the risk for allergic sensitization.2,24
Furthermore, the response to vitamin D supplementation
may differ between individuals owing to genetic and epige-
netic factors.25Sensitization of Infants 5
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randomized, controlled trial with good adherence to the
study protocol.12 We measured 25(OH)D concentrations
repeatedly, and allergy outcomes included both clinical
and laboratory data. As a limitation, we acknowledge the
study to be a secondary analysis of a randomized trial
with the sample size not computed for the allergy out-
comes. Some of the observed findings could have arisen
by chance owing to the multiple comparisons performed.
The initial trial length was for 24 months, but unfortu-
nately we were able to measure IgE levels only at the
12 months of follow-up. However, food sensitization prev-
alence is highest at 12 months of age and may identify chil-
dren at risk for subsequent allergic disease. In addition,
bronchiolitis and wheezing in infancy may serve as early
predictors of asthma justifying the selected time-point
for outcome evaluation.26,27 Our data on clinical allergic
diseases were based on parental report, which may have
led to bias. At 12 months, the prevalence of food allergies
in our study was similar to that of the general population,
whereas, for example, wheezing was most likely underre-
ported by parents.28,29 However, by measurement of spe-
cific IgE levels from a large sample of healthy infants, we
were able to obtain unbiased data on allergic sensitization.
Furthermore, it is likely that the reporting error would be
similar in both intervention groups. Our study lacked
vitamin D-deficient infants, which is most likely the result
of current health policies in Finland, that is, the recom-
mendation of daily 10 mg vitamin D supplementation to
all pregnant women and fortification of food products
with vitamin D.30 Still, the improved vitamin D status at
birth enabled us to detect the positive association of high
cord blood 25(OH)D concentration with allergic sensitiza-
tion, which emphasizes the need for further studies con-
cerning possible adverse health effects of high 25(OH)D
levels and the optimal vitamin D dosage.31
Conclusions
We observed that, in vitamin D-sufficient infants, higher
vitamin D supplementation did not decrease allergic sensiti-
zation, allergic diseases, or wheezing during the first year of
life. However, the risk for allergic sensitization was higher
in infants with high cord blood 25(OH)D concentration,
suggesting that high vitamin D levels at birth may modify
the immune response related to allergy development. How-
ever, the connection of vitamin D and allergy is complex
and requires further studies. Because allergic diseases mani-
fest more clearly in later childhood, long-term follow-up of
the study cohort is essential. n
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